Galectin Therapeutics Total Liabilities

Galectin Therapeutics (GALT) currently reports a total liabilities of $150M as of March 2026. That compares with $120M in the prior-year period — up 19.9% year over year. Use the charts on this page to explore Galectin Therapeutics's total liabilities history and peer comparisons.

Galectin Therapeutics's total liabilities increased from $120M to $150M — a 19.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Galectin Therapeutics reported $150M in total liabilities as of March 2026. That compares with $120M in the prior-year period — up 19.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Galectin Therapeutics, and consider following GALT for alerts when major investors trade the stock.

Galectin Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GALT with unrelated industries.